Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 4/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719414 | 0.88 | MEN1 (0.42) | MEN1KMT2AMAPTEPHX2SCN4A | |
| SCHEMBL1640155 | 0.81 | MEN1 (0.36) | MEN1KMT2AMAPTEPHX2SCN4A | |
| SCHEMBL1034047 | 0.81 | KIF11 (0.36) | MEN1KMT2AMAPTEPHX2SCN4A | |
| SCHEMBL1034624 | 0.79 | RORA (0.34) | MEN1KMT2AMAPTEPHX2SCN4A | |
| SCHEMBL12095255 | 0.79 | BCKDK (0.41) | MAPT | |
| SCHEMBL1034046 | 0.79 | GSK3B (0.33) | MEN1KMT2AMAPTEPHX2SCN4A | |
| SCHEMBL17341211 | 0.78 | EPHX2 (0.41) | MEN1KMT2AMAPTEPHX2SCN4A | |
| SCHEMBL1030697 | 0.77 | PTGER1 (0.34) | MAPTEPHX2SCN4ADYRK1AKIF11 | |
| SCHEMBL16934958 | 0.76 | MCL1 (0.42) | MEN1KMT2AMAPT | |
| SCHEMBL4655105 | 0.76 | CYP2A6 (0.40) | MEN1KMT2ADYRK1AHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3424917-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
| EP-2277874-B1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO (JP) | 2018-06-27 | — | — | EP | disclosed |
| CN-104672220-A | Activating agent for peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO | 2015-06-03 | — | — | CN | disclosed |
| CN-102675341-B | Dihydro-triazole and benzo two nitrogen heterocyclic ketones compound, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB | 2015-02-25 | — | — | CN | disclosed |
| CN-102083810-B | Activator of peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO.,LTD. (JP) | 2014-10-29 | — | — | CN | disclosed |
| US-8778932-B2 | Dihydro-oxazolobenzodiazepinone compounds, a process for there preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| US-8648208-B2 | Activating agent for peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO. LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| EP-2497774-B1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB (FR) | 2013-10-16 | — | — | EP | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| CN-102675341-A | Dihydro-triazole and benzo two nitrogen heterocyclic ketones compound, processes for their preparation and pharmaceutical compositions comprising these compounds | SERVIER LAB | 2012-09-19 | — | — | CN | disclosed |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | EGIS GYOGYSZERGYAR NYRT (HU) | 2012-09-13 | — | — | US | disclosed |
| EP-2497774-A1 | Dihydro-oxazolobenzodiazepinone derivatives, processes for their preparation and pharmaceutical compositions comprising these compounds | Les Laboratoires Servier (FR) | 2012-09-12 | — | — | EP | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| CN-102083810-A | Activator of peroxisome proliferator activated receptor | NIPPON CHEMIPHAR CO | 2011-06-01 | — | — | CN | disclosed |
| US-20110098480-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | NIPPON CHEMIPHAR CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| CN-102015641-A | Heterocyclic compound | TAKEDA PHARMACEUTICAL | 2011-04-13 | — | — | CN | disclosed |
| EP-2277874-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885MAPT 4533/4885 |
| US-20110098480-A1 | ACTIVATING AGENT FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR | PPARA, PPARG, PPARD | MEN1 4646/4885KMT2A 2414/4885MAPT 4843/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MEN1 444/4885KMT2A 1298/4885MAPT 4533/4885 |
| US-20120232065-A1 | DIHYDRO-OXAZOLOBENZODIAZEPINONE COMPOUNDS, A PROCESS FOR THERE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GRIN2C, GRIN2B, GRIN2A | MEN1 4116/4885KMT2A 1335/4885MAPT 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.